11 December 2023
11 December 2023
The approval is based on data from two paediatric clinical studies of invasive aspergillosis and invasive mucormycosis patients.
Pfizer has added the EU to its growing number of markets for its targeted immunotherapy intended for relapsed/refractory multiple myeloma (RRMM).
The combination therapy of Keytruda and Lenvima failed to meet the dual primary endpoints in a Phase III advanced endometrial cancer trial.
VIPER-101 has received FDA clearance to begin clinical studies in the midst of a broader investigation on CAR-T cell therapies.
NextPoint plans to kickstart the first-in-human Phase I clinical trial in early 2024, investigating NPX887 in patients with HHLA2-positive tumours.
Following the dosing of the first patient in Phase II atopic dermatitis trial, Kymera received a $15m milestone payment from Sanofi as part of the global licensing agreement.
The Harbour Mice platform can aid in developing therapeutic antibodies and expedite the discovery and development of treatments.
Ferring will receive exclusive rights for the development, production and marketing of microbiome-based biotherapeutics.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
